Efficacy and Safety of NVX-CoV2705
← catalyst calendarNCT07086222 · readout in 91 d
Sponsored by Novavax (industry) · NVAX — their whole pipeline →. With Sanofi.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
6,500actual
Sites
99
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-20 | actual | When the study began enrolling |
| Primary completion | 2026-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- COVID-19
- Sars-CoV-2 Infection
Interventions
- Biological: NVX-CoV2705 — also filed as Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M
- Biological: Placebo
Primary outcome
what the primary-completion date above is the date OFFirst episode of PCR-positive symptomatic COVID 19
measured Day 0 to Day 180
Permalink · NVAX's whole pipeline · Catalyst calendar · Every registered study · What changed